NCT05319015View on ClinicalTrials.gov

Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 6, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

August 31, 2026

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Neoadjuvant Lenvatinib

20 mg PO daily for 12 weeks prior to surgery

DRUG

Neoadjuvant Pembrolizumab

200 mg IV every 3 weeks for 4 doses prior to surgery

PROCEDURE

Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection

Resection of locally advanced RCC with IVC tumor thrombus

DRUG

Adjuvant Pembrolizumab

200 mg IV every 3 weeks for up to 13 doses after surgery

Trial Locations (1)

75390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER